Nektar Therapeutics

Valuation Analysis

About the Company

Nektar Therapeutics en bref

Nektar Therapeutics (NKTR) is currently trading at 53,16 € with a market capitalization of 1,8 Md €. The 52-week range spans from 7,21 € to 95,02 €; the current price is 44.1% below the yearly high. Year-over-year revenue growth stands at +3.8%.

💰 Dividende

Nektar Therapeutics currently does not pay a dividend. The company typically reinvests its earnings into growth initiatives and product development.

📊 Avis des analystes

8 analystes évaluent Nektar Therapeutics (NKTR) au consensus : Achat Fort. L'objectif de cours moyen est de 133,60 €, soit un potentiel de +151.31% par rapport au cours actuel. La fourchette des objectifs de cours des analystes va de 69,74 € à 167,38 €.

Nektar Therapeutics : la thèse d'investissement en détail

Nektar Therapeutics (NKTR) operates in the Healthcare — specifically Biotechnology — and is headquartered in United States. Below is a structured read of the investment case built directly from the latest fundamentals, valuation multiples, analyst positioning and smart-money flows. Each section translates raw numbers into the investment logic they imply, so you can decide whether the risk/reward fits your portfolio.

Le scénario haussier

With a gross margin near 100%, the company sits in the top tier of its industry — these are the kinds of structural margins that protect earnings during downturns. Wall Street consensus sits at Strong Buy with an average price target implying roughly 151.31% upside from current levels — analyst sentiment is firmly constructive.

Le scénario baissier

Revenue growth has slowed to just 3.8%, which is below nominal GDP — the business is no longer outgrowing the broader economy. Net margins remain negative, meaning every euro of revenue is still producing losses — the path to profitability is the central question for shareholders. Short interest sits at 15.07% of float — a meaningful contingent of professionals is positioned for the share to fall, which deserves attention even if their thesis may turn out to be wrong.

Valorisation en contexte

With a PEG ratio of 0.31, the price-to-earnings multiple is actually below the company's growth rate — classic value-meets-growth territory that Peter Lynch would have called a 'GARP' opportunity.

À surveiller

• The analyst consensus price target implies 151.31% upside — if the next two quarters confirm the underlying thesis, target hikes typically follow.

Thèse d'investissement : forces et faiblesses

Aperçu technique

Price shows short-term weakness (below 50d MA) but is still in a longer-term uptrend (above 200d MA).

Profil de risque

The data points to market-like volatility, elevated short interest (15.07%).

Trading Data

Related Stocks in the Same Sector

Where can I buy Nektar Therapeutics?

Compare top-rated brokers — low fees, trusted providers, fully regulated.